Bay98-7196, Dose Finding / POC Study

PHASE2CompletedINTERVENTIONAL
Enrollment

319

Participants

Timeline

Start Date

October 16, 2014

Primary Completion Date

October 24, 2016

Study Completion Date

October 24, 2016

Conditions
Endometriosis
Interventions
DRUG

Placebo

Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection

DRUG

Levonorgestrel

Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection

DRUG

Anastrozole

Participants received Anastrozole 300 µg/d or 600 µg/d or 1050 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection

DRUG

Lupron / Leuprolide acetate

Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Lupron / Leuprolide acetate 11.25 mg 3-months depot intramuscular injection

Trial Locations (117)

1000

Bruxelles - Brussel

1011

Lausanne

1070

Bruxelles - Brussel

1090

Vienna

1383

Asker

2100

Copenhagen

2650

Edegem

3010

Bern

3111

Tønsberg

4020

Linz

6000

Lucerne

6020

Innsbruck

7006

Trondheim

8036

Barcelona

8200

Aarhus N

8450

Stokmarknes

9000

Ghent

9019

Tromsø

9500

Villach

10787

Berlin

12200

Berlin

19104

Philadelphia

20357

Hamburg

20520

Turku

22587

Hamburg

27103

Winston-Salem

27408

Greensboro

27713

Durham

28023

Aravaca

28223

Pozuelo de Alarcón

28400

Collado Villalba

30328

Sandy Springs

30338

Atlanta

32605

Gainesville

34652

New Port Richey

37001

České Budějovice

37404

Chattanooga

38889

Blankenburg

39003

Tábor

39701

Písek

40100

Jyväskylä

41014

Seville

43213

Columbus

45409

Dayton

46010

Valencia

46014

Valencia

48034

Detroit

48187

Canton

48604

Saginaw

50931

Cologne

52074

Aachen

53562

Madison

60463

Palos Heights

60611

Chicago

67226

Wichita

68165

Mannheim

68510

Lincoln

70072

Marrero

70100

Kuopio

76199

Karlsruhe

81675

München

90100

Oulu

91054

Erlangen

92108

San Diego

98105

Seattle

94158-2509

San Francisco

07754

Neptune City

08536

Plainsboro

L8S 4K1

Hamilton

K1H 7W9

Ottawa

M5C 2T2

Toronto

H4P 2S4

Montreal

G1S 2L6

Québec

602 00

Brno

625 00

Brno

500 03

Hradec Králové

772 00

Olomouc

326 00

Pilsen

Unknown

Prague

Almere Stad

Frauenklinik

DK-5000

Odense C

02100

Espoo

00510

Helsinki

05850

Hyvinkää

01744

Dippoldiswalde

01307

Dresden

06406

Bernburg

07743

Jena

800-0296

Kitakyushu

006-8555

Sapporo

060-0031

Sapporo

060-0061

Sapporo

060-0807

Sapporo

666-0125

Kawanishi

920-8530

Kanazawa

710-0824

Kurashiki

589-8511

Sayama

430-0929

Hamamatsu

113-8431

Bunkyo-ku

107-0052

Minatoku

141-8625

Shinagawa-ku

861-8520

Kumamoto

381-8551

Nagano

543-0023

Osaka

9700 RB

Groningen

3435 CM

Nieuwegein

8025 AB

Zwolle

15- 224

Bialystok

40-724

Katowice

31-121

Krakow

90-602

Lodz

20-632

Lublin

71-434

Szczecin

21-010

Łęczna

08003

Barcelona

01009

Vitoria-Gasteiz

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY

NCT02203331 - Bay98-7196, Dose Finding / POC Study | Biotech Hunter | Biotech Hunter